Bio-Technology General Israel (BTG) is an integrated biopharmaceutical services company that develops and manufactures healthcare products derived from genetic engineering and biotechnology processes. BTGs Biolon, first introduced in 1993, is an injectable system containing 1% fermentation-derived sodium hyaluronate (NaHA) used as a viscoelastic aid in cataract and other ophthalmic surgeries. Euflexxa is a treatment to help relieve knee pain due to osteoarthritis (OA). It is used by thousands of people to help manage OA knee pain and stay active. Containing 1% fermentation-derived sodium hyaluronate, Euflexxa is intended for intra-articular injection into the knee. Developed in the 1980s, BTGs recombinant human growth hormone (somatropin for injection or hGH) first gained regulatory approval in 1988. It is identical to natural human growth hormone synthesized by the pituitary gland, and is used to treat Turner syndrome and growth hormone deficiency in children. BTG is a wholly owned subsidiary of Ferring Pharmaceuticals.